This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi
by Zacks Equity Research
Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.
Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark
by Zacks Equity Research
Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.
Philips (PHG) Expands Mobile C-arm Portfolio With Zenition 30
by Zacks Equity Research
Philips (PHG) expands its mobile C-arm lineup with Zenition 30, which provides surgeons with more control and customization.
Masimo's (MASI) Inks Agreement to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.
Masimo's (MASI) Stork Baby Monitor Now Available Across U.S.
by Zacks Equity Research
The latest U.S. availability of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise
by Zacks Equity Research
Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.
Masimo (MASI) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Masimo (MASI) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Masimo (MASI) Q2 Earnings Miss Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of -27.91% and 0.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 171.43% and 4.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales
by Zacks Equity Research
Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Masimo's (MASI) solid product suite raises optimism about the stock.
Here's Why You Should Retain Molina (MOH) in Your Portfolio
by Zacks Equity Research
Numerous contract wins, financial flexibility and strong performing Medicaid and Medicare segments poise Molina (MOH) well for growth.
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Masimo (MASI) have performed compared to their sector so far this year.
Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients
by Zacks Equity Research
Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.
Masimo's (MASI) Launch to Serve the Personalized Hearables Market
by Zacks Equity Research
Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.
Acadia Healthcare (ACHC) Expands With New Hospital in Michigan
by Zacks Equity Research
Acadia Healthcare's (ACHC) partnership with Bronson Healthcare to expand its footprint in Michigan with Bronson Behavioral Health Hospital.
Masimo (MASI) Inks Deals for Patient Monitoring Technologies
by Zacks Equity Research
Masimo's (MASI) advanced monitoring technologies and solutions attract new customers looking for better patient care, using remote and centralized surveillance, and seamless data transfer to EMRs.
Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.
Masimo (MASI) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo's (MASI) New FDA Approval to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) Radius VSM is expected to equip any hospital bed with comprehensive monitoring and offer more personalized care without additional bedside equipment.
UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health
by Zacks Equity Research
UnitedHealth (UNH) offers to combine its Optum business with Amedisys to expand its reach in the healthcare-at-home market.
Here's Why Investors Should Hold Universal Health (UHS) Now
by Zacks Equity Research
Universal Health (UHS) benefits from growing patient volumes, sound segmental performance and a solid capital position.
Zacks Industry Outlook Highlights Hologic, Masimo and Integer
by Zacks Equity Research
Hologic, Masimo and Integer have been highlighted in this Industry Outlook article.
Masimo's (MASI) Platform Expansion to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.